Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jun;12(3):363-78.
doi: 10.2217/whe.16.4. Epub 2016 May 24.

Targeted therapy in ovarian cancer

Hui Jun Lim  1 , William Ledger  2
Affiliations
Review

Targeted therapy in ovarian cancer

Hui Jun Lim et al. Womens Health (Lond). 2016 Jun.

Abstract

Among female-specific cancers worldwide, ovarian cancer is the leading cause of death from gynecologic malignancy in the western world. Despite radical surgery and initial high response rates to first-line chemotherapy, up to 70% of patients experience relapses with a median progression-free survival of 12-18 months. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian cancer. This review aims to assess current understanding of targeted therapy in ovarian cancer and evaluate the evidence for targeting growth-dependent mechanisms involved in its pathogenesis. Of the many targeted therapies currently under evaluation, the most promising strategies developed thus far are antiangiogenic agents and PARP inhibitors.

Keywords: PARP inhibitors; VEGF inhibitors; combination therapy; ovarian cancer; targeted therapy.

PubMed Disclaimer

References

    1. Papers of special note have been highlighted as: • of interest; •• of considerable interest
    1. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin. Obstet. Gynecol. 55(1), 3–23 (2012). - PubMed
    1. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol. Oncol. Clin. North Am. 26(1), 1–12 (2012). - PMC - PubMed
    1. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307(4), 382–389 (2012). - PMC - PubMed
    1. Goff BA. Advanced ovarian cancer: what should be the standard of care? J. Gynecol. Oncol. 24(1), 83–91 (2013). - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources